grant

Division of Cancer Treatment and Diagnosis- Operational Task Order

Organization LEIDOS BIOMEDICAL RESEARCH, INC.Location FREDERICK, UNITED STATESPosted 31 Aug 2025Deadline 30 Aug 2026
NIHUS FederalResearch GrantFY2025Anti-Cancer AgentsAntineoplastic AgentsAntineoplastic DrugsAntineoplasticsAssayBioassayBiologicalBiological AgentBiological AssayBiological MarkersBiological ProductsCancer DrugCancersClinicClinicalClinical TrialsCollaborationsContracting OpportunitiesContractsCorrelative StudyCyclic GMPData ScienceData SystemsDevelopmentDiagnosticDiagnostic testsDiscipline of NursingDivision of Cancer Treatment and DiagnosisDrug KineticsDrugsEvaluationFundingGenomicsGuanosine Cyclic MonophosphateHigh Throughput AssayIT SystemsImageIn VitroInformaticsInformation SystemsInformation Technology SystemsLaboratoriesLibrariesMalignant NeoplasmsMalignant TumorMedicalMedicationMolecularNanotechnologyNational Institutes of HealthNatural ProductsNeoplastic Disease Chemotherapeutic AgentsNew AgentsNursingNursing FieldNursing ProfessionPDX modelPatient derived xenograftPatientsPerformancePharmaceutical PreparationsPharmacokineticsPharmacologyPre-Clinical ModelPrecision medicine trialPreclinical ModelsProductionRadiation ChemistryRadiochemistryRadiopharmaceutical CompoundRadiopharmaceuticalsResearchServicesTechnologyTestingTherapeutic InterventionToxicologyTranslational ResearchTranslational ScienceTumor-Specific Treatment AgentsUnited States National Institutes of HealthWorkanti-cancer drugassay developmentbio-markersbiobankbiologicbiologic markerbiologicsbiomarkerbiopharmaceuticalbiopharmaceutical companybiopharmaceutical industrybiorepositorybiotherapeutic agentcGMPclinical centerdepositorydevelopmentaldrug developmentdrug discoverydrug productiondrug/agenthigh throughput screeningimagingin vivointervention therapymalignancymanufacturenano technano technologynano-technologicalnanotechnanotechnologicalnaturally occurring productneoplasm/cancernew diagnosticsnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynext generation diagnosticsnovel diagnosticsnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachpatient derived xenograft modelpharmacodynamic biomarkerpharmacodynamic markerprogramsradioactive drugsradiotherapeutic drugsrepositorytranslation researchtranslational investigationtumor
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

The Division of Cancer Treatment and Diagnosis (DCTD) supports the development of novel diagnostic and therapeutic approaches for cancer by expediting the initial and subsequent large-scale testing of new agents, biomarkers, imaging tests, and other diagnostic and therapeutic interventions in patients. Within DCTD, eight major programs and a patient clinic work together to bring unique molecules, diagnostic tests, and therapeutic interventions from the laboratory bench to the patient bedside. Activities supported under this contract include: isolation and evaluation of natural products; molecular pharmacology; high-throughput screening of compound libraries; pharmacodynamic marker and pharmacokinetic assay development and utilization in clinical trials; drug toxicology research; information systems, technologies, and data science; drug discovery; radiochemistry and radioactive drug production; archival of clinical trial images, in vitro and in vivo translational research; repository support for natural products, patient-derived xenografts, tumors and biologic anti-cancer agents; a biopharmaceutical production facility; medical writers; nursing support services for clinical trials performed in the NIH Clinical Center, correlative studies in collaboration with biopharmaceutical companies; support for precision medicine trials; advanced genomics capabilities supporting tumor evaluation in pre-clinical models and clinical trials; patient biorepositories for NCI-funded clinical trials; nanotechnology characterization and evaluation.

Grant Number: 75N91019D00024-0-759102500016-16
NIH Institute/Center: NIH

Principal Investigator: lynn briscoe

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →